Fig. 3

Bevacizumab response stratified by the expression level of miR-142. A Bevacizumab conferred significant improvements in PFS for patients with high miR-142 expression (HR: 0.64, 95%CI: 0.47–0.87, Log-rank P = 0.004). B Bevacizumab conferred significant improvements in OS for patients with high miR-142 expression (HR: 0.59, 95%CI: 0.38–0.93, Log-rank P = 0.022). C Bevacizumab treatment conferred no significant improvements in PFS (HR: 0.90, 95%CI: 0.54–1.51, Log-rank P = 0.703) for patients with low miR-142 expression. D Bevacizumab treatment conferred no significant improvements in OS (HR: 1.12, 95%CI: 0.46–2.75, Log-rank P = 0.806) for patients with low miR-142 expression